General Archive
-
News releasesBrain inflammation targeted in first drug discovery project from £3m Dementia Consortium
Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at…
-
News releases
MRC Technology and Peptinnovate collaborate on therapeutics for bone diseases
Collaboration to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
-
News releases
Poster prize for presentation at Chemistry in Health Conference
Ela Smiljanic-Hurley’s poster presentation at the Chemistry in Health Conference 2015, held on 26 May at the Royal Society of…
-
News releases
Dementia care digital platform launched by partnership including MRC Technology
Brain health company IXICO launched a digital platform, Project Cygnus, to support patients with the diseases that cause dementia. IXICO…
-
News releases
MRC Technology collaborates with NYU School of Medicine to develop biologics for inflammatory bone disease
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory…
-
News releases
MRC Technology appoints Finance Director
MRC Technology has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim…
-
News releases
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
MRC Technology announced it has negotiated a licence for ultrastable gold supports developed at the MRCLaboratory of Molecular Biology, with…
-
News releases
MRC Technology and Cyclofluidic announce the successful completion of a hit optimisation project
MRC Technology (MRCT) and Cyclofluidic Ltd have announced the successful completion of their collaboration to identify and optimise drug-like molecules…
-
News releases
First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
Pembrolizumab, humanized by MRC Technology, is the the first drug to be approved through the Early Access to Medicine Scheme…
-
News releases
Respiratory ‘Call for Targets’ launched
‘Call for targets’ launched to find new therapeutic concepts for treatment of respiratory disease, including conditions such as allergy, acute…
-
News releases
MRC Technology appoints General Counsel and Company Secretary
Dr Edward Bliss appointed in new role of General Counsel and Company Secretary.
-
News releases
MRC Technology to manage Diabetes UK’s IP
MRC Technology has signed an agreement with Diabetes UK to manage its intellectual property (IP). The partnership will enable Diabetes…